Type 2 Diabetes: Endothelial dysfunction and Exercise

Article information

J Exerc Nutrition Biochem. 2014;18(3):239-247
Publication date (electronic) : 2014 September 26
doi : https://doi.org/10.5717/jenb.2014.18.3.239
1Division of Clinical and Translational Science, Georgia Regents University, Georgia, USA
2School of Global Sport Studies, Korea University, Sejong, Korea
*Corresponding author: Sangho Kim, Tel. 82-010-7403-3838, Email. ksh1905@korea.ac.kr
Received 2014 August 4; Revised 2014 September 16; Accepted 2014 September 26.



Vascular endothelial dysfunction is an early marker of atherosclerosis characterized by decreased nitric oxide bioavailability in the vascular endothelium and smooth muscle cells. Recently, some animal models and in vitro trials demonstrated that excessive superoxide production from mitochondria within vascular endothelial cells played a role in the pathogenesis of atherosclerosis in type 2 diabetes. This review provides a systematic assessment of the effectiveness of exercise to identify effective approaches to recognize diabetes risk and prevent progression to heart disease.


A systematic literature search was conducted to retrieve articles from 1979 to 2013 using the following databases: the MEDLINE, PubMed. Articles had to describe an intervention that physical activity and exercise to identify effective approaches to heart and vascular endothelium.


Currently, physical activity and exercise guidelines aimed to improve cardiovascular health in patients with type 2 diabetes are nonspecific. Benefit of aerobic exercise training on vascular endothelial function in type 2 diabetic patients is still controversial.


it is necessary to demonstrate the mechanism of endothelial dysfunction from live human tissues so that we can provide more specific exercise training regimens to enhance cardiovascular health in type 2 diabetic patients.


Diabetes mellitus, a complex disorder, is a combination of metabolic disorders associated with hyperglycemia due to inadequate insulin production or insulin action [18]. Diabetes is a world-wide problem affecting approximately 300 million people. In Korea, diabetic population is gradually growing. Approximately 15,000 people die due to complications associated with diabetes every year [90]. Diabetes is classified into two groups, type 1 and type 2. Type 1 is characterized by beta-cell destruction leading to insulin deficiency due to autoantibody formation. Type 2 is characterized by insulin resistance and eventual reduced insulin secretion due to pancreatic scaring and loss of beta-cells. Type 2 diabetes, comprising 90-95% of all cases of diabetes mellitus, is one of the most lethal diseases in the world [88].

The main cause of death in type 2 diabetes is cardiovascular disease, specifically atherosclerosis [58]. Atherosclerosis is initiated by sequences of alterations in the structure and function of the vascular endothelium [2,11]. The exact etiology of vascular endothelial dysfunction is complex without well understanding. However, experimental evidences suggest that imbalance between oxidative stress and host antioxidant defense along with pro-inflammatory and anti-inflammatory factors play critical roles in early vascular endothelial dysfunction [58]. Some (but not all) previous exercise interventions have resulted in enhanced vascular endothelial function in type 2 diabetics. However, limited information is available on the most effective type of exercise training program or mechanisms responsible for the improvements seen in vascular endothelial function. Thus, this review has the following three aims: 1) to introduce presumed diabetes-specific mechanisms responsible for dysfunctional vascular endothelium; 2) to summarize and investigate current evidence of the effect of exercise training on conduit vessel endothelial function in type 2 diabetic patients; and 3) to present possible future directions to what should be further explored to expand our knowledge on this research topic.

Relaxation of vascular endothelium: a major determinant for vascular integrity

Human vasculature is composed of three layers: the endothelium (intima), smooth muscle cells (media), and surrounding elastic and connective tissues (adventitia). The vascular endothelium comprises the innermost layer of the vasculature, which directly senses changes in blood flow and interacts with hormones and neurotransmitters through various receptor-ligand complexes at its membrane, producing vasoactive agents such as nitric oxide (NO), prostacyclin (PGI) , endothelium-derived hyperpolarizing factors (EDHF) , and endothelin-1 [45,55,65]. These agents control vascular tone at the vascular smooth muscle level either through vasoconstriction or vasodilatation. The vasculature is relaxed or dilated if the effect of dilatory agents overrides that of constricting agents, such as the basal sympathetic tone and endothelin-1, whereas vasoconstriction occurs if the dilatory signals are overpowered.

Nitric oxide or NO, the most prominent vasodilatory agent, is produced by the L-arginine - endothelial nitric oxide synthase (eNOS) pathway as a byproduct. The L-citrulline in the vascular endothelium then diffuses into vascular smooth muscle cells and facilitates soluble guanylyl cyclase to convert guanosine triphosphate (GTP) to cyclic guanosine monophosphaste (cGMP), which in turn leads to calcium ion movement into the sarcoplasmic reticulum, decreasing calcium ion concentration within the cytoplasm of smooth muscle cells, thus causing the vascular smooth muscle cells lose their tonicity [19,31,37,59,78]. Similarly, PGIs are produced when cyclooxygenase (COX) uses arachidonic acid (AA) as a substrate in vascular endothelium to move into neighboring vascular smooth muscle cells, which then convert adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP) through activated adenylyl cyclase (AC), inducing vasodilation as a result of decreased calcium ion concentration in vascular smooth muscle cells [4,36,44].

The endothelin derived hyperpolarizing factor (EDHF) signaling pathway still remains to be elucidated although there have been many studies [1,13,24,37,52,56]. However, it is known that EDHFs are generated by the enzymatic activity of cytochrome P-450 within the golgi apparaturs in endothelial cells. Like COX, AA used as a substrate for the enzymatic activity of cytochrome P-450 eventually leads to EDHF stimulation or opening of potassium ion channels on the vascular smooth muscle cell membrane, resulting in hyperpolarization of vascular smooth muscle cells. This potassium mediated hyperpolarization reduces the duration of calcium ion channel opening, resulting in decreased calcium ion influx into vascular smooth muscle cells which leads to vascular smooth muscle relaxation [47,55,76]. Endothelin-1 (ET-1) is an endogenous constricting agent produced in vascular endothelial cells that acts as a vascular smooth muscle constricting agent after binding to ET-1 receptors (ET-A or B receptors) on the vascular smooth muscle cell membrane [46,49,70,84]. The endothelium-dependent vasoregulatory signaling pathways are illustrated in Fig. 1.

Fig. 1.

Endothelium-dependent vasoregulators.

As previously mentioned, the modulation of human vasculatures is very complicated since there are numerous physiological mediators involved neural (release of norepinephrine) and humoral (angiotensin II and epinephrine) regulators which systemically influence and interact with more local regulators, such as the myogenic response and endothelium-derived relaxing factors (EDRF: NO, PGI, and EDHF) [14,30,60,80]. However, EDRFs are considered to be the most important vasoregulators because they override resting vascular tone controlled by systemic regulators and fine tuning other local mediators [60].

Nitric oxide (NO) also prevents abnormal growth of vascular smooth muscle cells and maintains optimal, healthy vascular wall structure [10,43]. Functionally, NO is the major vasodilator modulating systemic vascular resistance, whereas PGI and EDHF are less influential by providing supplementary means for vasodilatation [12]. Improved NO production along with NO bioavailability depend on the eNOS substrate L-arginine’s availability, eNOS phosphorylation and dimeric coupling, availability of eNOS cofactors (tetrahydrobipterin: BH4, heat shock protein-90: HSP-90, and calmodulin), and a balance between oxidants and antioxidants [3,20,38,53,68,69,72]. Thus, it is important to assess systemic biomarkers with NO-mediated vasodilation in order to understand the mechanisms involved in the structural and functional changes that occur in diabetes patients.

Potential mechanisms of diabetes-mediated vascular endothelial dysfunction

Unlike other tissues and cells not affected by abnormal systemic glucose concentration, vascular endothelium is very sensitive to alterations of blood glucose. Therefore, vascular endothelium is likely to be a main target of hyperglycemic damage [40]. Oxidative stress has emerged as a major player in the cause of vascular endothelial dysfunction in other chronic diseases such as diabetes as well as in normal aging. However, in diabetes, it has been recognized that hyperglycemia-induced generation of reactive oxygen species (ROS) in the vascular endothelium is the foundation of micro- and macro-vascular complications [5].

Four putative mechanisms of diabetes-mediated vascular complications have been indicated by well-designed molecular studies. Firstly, the altered role of aldose reductase through sorbitol aldose reductase pathway increases oxidative stress, thus inducing the formation of uncoupled eNOS. Unlike its normal function to convert aldehyde to inactive alcohol, aldose reductase converts glucose into sorbitol which abnormally increases intracellular glucose concentration. During this signaling process, aldose reductase uses nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor. Thus, the absolute quantity of NADPH, a major cofactor in regenerating reduced glutathione, is decreased, further augmenting intracellular oxidative stress [34,81]. Secondly, hyperglycemia-induced advanced glycation end products (AGEs) in vascular endothelium cause increased production of ROS and inflammatory cytokines as well as increased receptor (RAGE) activity and pro-atherogenic lipoprotein modification [35,86]. Thirdly, an overall increase in diacylglycerol (DAG) production leads to protein kinase C (PKC) activation. DAG, a mediator in the second messenger system, is recruited for intracellular lipid metabolism. After DAG activation, PKC is involved not only in eNOS activity, but also in a lot of gene expression and cytokine production in the vascular endothelium. Activated PKC increases ROS generation by NADPH oxidase, vascular adhesion molecules, pro-inflammatory cytokines, and growth factors, but decreases eNOS activity, resulting in a decrease of overall NO bioavailability, a major characteristic of vascular endothelial dysfunction [27,33,61,64,82]. Fourthly, fructose 6-phosphate can be converted into glucosamine 6-phosphate by glucosamine 6-phosphate transferase through the hexosamine pathway in the hyperglycemic cellular environment, instead of being converted to glyceraldehyde 3-phosphate in the glycolytic pathway. Uridine diphosphate (UDP) N-acetyl glucosamine, the cytosolic end product of the hexosamine pathway, decreases eNOS phosphorylation but increases transforming growth factor-β1 and plasminogen activator inhibitor-1 production, which in turn facilitates the pathological processes of diabetic vascular complications [25,42,71,85]. Currently, these four distinct mechanisms have not been directly associated with each other. However, they appear to have a common upstream inducer hyperglycemia and abnormally augmented ROS production along the electron transport chains (ETC) within vascular endothelial cell mitochondria [5].

According to Brownlee’s concept on the role of oxidative stress in diabetes-mediated vascular complications, hyperglycemia facilitates the rate of glycolysis and the Krebs cycle, which aberrantly generates more nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) and abnormally over-activates ETC. Once the ETC is activated, more hydrogen ions come out of the mitochondrial inner membrane which increase membrane potential [5]. To bring the membrane potential back down to normal, complex III in the ETC is blocked, electrons from coenzyme Q combined with oxygen molecules then generate more superoxide anions. However, hyperglycemia reduces both enzymatic (superoxide dismutase, catalase, and glutathione peroxidase) and non-enzymatic (vitamin E, coenzyme Q, lipoic acid, and glutathione) antioxidants through the over production of ROS [5]. Thus, the balance between oxidants and antioxidants is disrupted which becomes a main trigger of diabetic vascular complications.

Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a major ROS source in the cytosol, leads to augmented superoxide production in vascular endothelium in the presence of abnormal glucose concentrations [41]. Hyperglycemia and increased ROS also results in structural and functional abnormality of the eNOS system. Insulin resistance, another major symptom of diabetes, inhibits eNOS phosphorylation by down-regulating phosphoinositide 3-kinase and PI3K/Akt pathway in vascular endothelium, decreasing NO production and thus its bioavailability [87]. The increased generation of reactive nitrogen species (i.e., peroxynitrite) within the vascular endothelium in diabetics could be also due to hyperglycemia. These reactive nitrogen species help facilitate lipid peroxidation, nitrotyrosine production, and DNA modification, leading to cardiovascular complications such as atherosclerosis [89]. Activated vascular adhesion molecules pooled into vascular endothelium also contribute to atherosclerotic plaque development in diabetics [17]. Putative pathways related to hyperglycemia-induced vascular endothelial dysfunction are illustrated in Figure 2.

Fig. 2.

Putative pathways associated with hyperglycemia-induced vascular endothelial dysfunction.

Assessment of conduit artery endothelial function: Flow-mediated dilation (FMD)

Flow mediated dilation or FMD is the non-invasive gold-standard way to assess NO-mediated vascular endothelial function in response to a physiological stimulus as seen in reactive hyperemia. Since this methodological approach was introduced by Dr. Celermajer in the Lancet Journal in 1992, many cardiovascular physiologists who work on human subjects have employed and further developed this methodology [6,11,16,21,26,29,75,77]. Unlike other methods such as venous occlusion plethysmography which indirectly assesses changes in local smaller vessel blood flow as segmental volume changes of a limb in response to local invasive pharmacological stimulus (i.e., acetylcholine), FMD directly measures changes in larger conduit vessel diameter in response to reactive hyperemia, which occurs after 5 minutes of local limb blood flow occlusion [26]. FMD determines the dilatory capacity of larger vessels by determining the difference between the resting diameter and the diameter during peak reactive hyperemia. FMD also has a strong correlation with invasive coronary epicardial vasoreactivity when evaluating conduit artery function. It has benefits in assessing other important functional parameters such as blood flow, velocity and vascular conductance [16,29]. However, FMD requires experienced operator to perform it accurately. In addition, it needs unified guidelines and standardizations in order to have validity when comparing results to other studies. Recently, Dr. Dan Green’s group provided a methodological guideline to assess FMD [77]. Although there are differences in operators, equipment, devices, analysis tools, and software between laboratories, unified technical guidelines will help researchers to accurately measure and evaluate FMD, and to compare the outcomes found in different laboratories. Most importantly, vascular smooth muscle responsiveness to a nitric oxide donor (i.e., nitroglycerin) needs to be tested if FMD method is used in order to ensure that results are coming specifically in an endothelium-dependent manner. In many studies, the outcomes of FMD have been supported by assays of numerous systemic biomarkers. Since Dr. Feng and Dr. Colombo introduced and developed a state-of-the-art methodological approach which collects vascular endothelial cells by inserting guide wires into artery or vein via catheterization and evaluates local endothelial cell protein expressions using immunofluorescence, such method has provided an abundant amount of scientific evidence to understand the mechanisms associated with vascular endothelial function [9,22,23,28,32, 39,62,63,73,74]. Thus, assessing both systemic and local biomarkers with FMD would be a great methodological approach to understand the mechanisms involved in any functional changes.

Aerobic exercise training and vascular endothelial function in type 2 diabetic patients

Although there has been a substantial effort to promote vascular health in type 2 diabetic patients, only a few randomized controlled trials have tested the effect of aerobic exercise training on vascular endothelial function in type 2 diabetic patients with inconclusive and controversial results [54]. Some experimental evidence demonstrated a positive influence of regular physical activity and aerobic exercise on the improvement of the vascular endothelial function through systemic inflammatory biomarkers in diabetics. However, other studies indicated that regular aerobic exercise did not enhance the impaired endothelial function or systemic biomarkers in type 2 diabetic patients [15,48,50,51,57,66,88]. Although there has been a lot of attention on the effect of aerobic exercise on large conduit artery health mainly assessed by FMD, only a couple of studies have evaluated the effect of aerobic exercise training specifically on conduit artery endothelial function in type 2 diabetics [48,50]. According to the recent collaborative statement by the American College of Sports Medicine (ACSM) and the American Diabetes Association (ADA), either aerobic or combined exercise (aerobic & resistance training) is recommended to prevent diabetes and the associated complications specifically to improve diabetic vascular health [8]. However, the recommended guidelines for aerobic exercise training are still nonspecific without specific aerobic exercise regimen aimed specifically towards helping improve vascular endothelial function in type 2 diabetic patients. This is partly due to the fact the mechanisms of the beneficial effects that aerobic exercise training has on diabetic vascular complications have not yet been fully elucidated. Recently, Dr. Wisloff and his colleagues have demonstrated that 16 weeks of high-intensive interval training was greatly superior to moderate continuous exercise on the improvement of the vascular endothelial function, insulin signaling, and overall blood glucose in metabolic syndrome patients, including patients with prediabetes [79]. The proposed effects of high-intensity interval training has caused patients and health care providers alike to become skeptical on its benefits when considering its potential risks and secondary detrimental effects it might have on individuals who are not physically fit. However, it has been recently demonstrated that high-intensity interval training can be safely employed in patients of high risk groups such as those with heart failure, metabolic syndrome, coronary artery disease, or hypertension. High-intensity interval training has been tested to over 2000 hours of intervention without any negative events [67,79,83]. Accordingly, future studies should demonstrate the benefit of high-intensity interval training on vascular endothelial function in type 2 diabetic patients. Furthermore, the optimal training modality, intensity, frequency, and duration to improve impaired and dysfunctional diabetic vasculature should be emphasized.


Hyperglycemia and insulin resistance are representative characteristics of type 2 diabetes. Vascular endothelial cells are highly sensitive to hyperglycemia along with insulin resistance. Nitric oxide (NO) is a major constituent necessary to maintain vascular integrity and dilatory capacity. FMD is the gold standard measure to assess NO-mediated vascular endothelial function. Diabetes-mediated vascular complications have their own potential mechanisms. Increased ROS generation of endothelial mitochondria has been implicated as a common precursor mechanism in the formation of diabetic vascular complications. Even though some studies have explored the effects of exercise on the human vascular endothelial function and related mechanisms, the outcomes in these studies were not consistent. The mechanistic understanding was limited to some systemic inflammatory biomarkers. Thus, future studies need to demonstrate the optimal exercise regimen for impaired diabetic vasculature and to directly investigate related molecular and biochemical mechanisms involved in the induction and prevention of endothelial injury within collected vascular endothelial cells in addition to traditional systemic biomarkers.


1. Bellien J, Thuillez C, Joannides R. Role of endotheliumderived hyperpolarizing factor in the regulation of radial artery basal diameter and ndothelium-dependent dilatation in vivo. Clin Exp Pharmacol Physiol 2008;35(4):494–497. 18307748.
2. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23(2):168–175. 12588755.
3. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 1990;87(2):682–685. 1689048.
4. Brotherton AF, Hoak JC. Role of Ca2+ and cyclic AMP in the regulation of the production of prostacyclin by the vascular endothelium. Proc Natl Acad Sci U S A 1982;79(2):495–499. 6281772.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–1625. 15919781.
6. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340(8828):1111–1115. 1359209.
7. Clozel M, Fischli W. Human cultured endothelial cells do secrete endothelin-1. J Cardiovasc Pharmacol 1989;13 Suppl 5:S229–231. 2473322.
8. Colberg SR, Albright AL, Blissmer BJ, Braun B, Chasan-Taber L, Fernhall B, Sigal RJ. Exercise and type2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. Exercise and type 2 diabetes. Med Sci Sports Exerc 2010;42(12):2282–2303. 21084931.
9. Colombo PC, Ashton AW, Celaj S, Talreja A, Banchs JE, Dubois NB, Le Jemtel TH. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. J Appl Physiol 2002;92(3):1331–1338. 11842075.
10. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489–509. 9046979.
11. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39(2):257–265. 11788217.
12. Csanyi G, Gajda M, Franczyk-Zarow M, Kostogrys R, Gwozdz P, Mateuszuk L, Chlopicki S. Functional alterations in endothelial NO, PGI(2) and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins Other Lipid Mediat 2012;98(3-4):107–115. 22465673.
13. Dal-Ros S, Bronner C, Schott C, Kane MO, Chataigneau M, Schini-Kerth VB, Chataigneau T. Angiotensin II-induced hypertension is associated with a selective inhibition of endothelium-derived hyperpolarizing factormediated responses in the rat mesenteric artery. J Pharmacol Exp Ther 2009;328(2):478–486. 18984652.
14. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999;79(2):387–423. 10221985.
15. De Filippis E, Cusi K, Ocampo G, Berria R, Buck S, Consoli A, Mandarino LJ. Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91(12):4903–4910. 17018657.
16. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115(10):1285–1295. 17353456.
17. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alphatocopherol supplementation. Circulation 2000;102(2):191–196. 10889130.
18. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31 Suppl 1:S55–60. 18165338.
19. Diamond J, Chu EB. Possible role for cyclic GMP in endothelium-dependent relaxation of rabbit aorta by acetylcholine. Comparison with nitroglycerin. Res Commun Chem Pathol Pharmacol 1983;41(3):369–381. 6314456.
20. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399(6736):601–605. 10376603.
21. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ, Millasseau SC, Halcox JP. Non-invasive assessment of endothelial function: which technique? J Am Coll Cardiol 2006;48(9):1846–1850. 17084260.
22. Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR. Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 2008;7(6):805–812. 18782346.
23. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009;297(1):H425–432. 19465546.
24. Dora KA, Gallagher NT, McNeish A, Garland CJ. Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res 2008;102(10):1247–1255. 18403729.
25. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97(22):12222–12226. 11050244.
26. Eskurza I, Seals DR, DeSouza CA, Tanaka H. Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans. Am J Cardiol 2001;88(9):1067–1069. 11704016.
27. Feener EP, Xia P, Inoguchi T, Shiba T, Kunisaki M, King GL. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib Nephrol 1996;118:180–187. 8744056.
28. Feng L, Stern DM, Pile-Spellman J. Human endothelium: endovascular biopsy and molecular analysis. Radiology 1999;212(3):655–664. 10478228.
29. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation 2012;126(6):753–767. 22869857.
30. Floras JS, Aylward PE, Victor RG, Mark AL, Abboud FM. Epinephrine facilitates neurogenic vasoconstriction in humans. J Clin Invest 1988;81(4):1265–1274. 3350973.
31. Furchgott RF, Jothianandan D. Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels 1991;28(1-3):52–61. 1848126.
32. Gavin KM, Seals DR, Silver AE, Moreau KL. Vascular endothelial estrogen receptor alpha is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. J Clin Endocrinol Metab 2009;94(9):3513–3520. 19509105.
33. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010;106(8):1319–1331. 20431074.
34. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107(9):1058–1070. 21030723.
35. Goldin A, Beckman JA., Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114(6):597–605. 16894049.
36. Gottlieb AL, Lippton HL, Parey SE, Paustian PW, Kadowitz PJ. Blockade of vasoconstrictor responses by prostacyclin (PGI2), PGE2, and PGE1 in the rabbit hindquarters vascular bed. Prostaglandins Med 1980;4(1):1–11. 6992175.
37. He GW. Nitric oxide and endothelium-derived hyperpolarizing factor in human arteries and veins. J Card Surg 2002;17(4):317–323. 12546079.
38. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104(22):2673–2678. 11723017.
39. Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Christou DD. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond) 2013;125(11):513–520. 23786536.
40. Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, King GL. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993;42(1):80–89. 7678404.
41. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Kim CD. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 2002;51(2):522–527. 11812764.
42. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998;101(1):160–169. 9421478.
43. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231(4736):405–407. 3941904.
44. Larrue J, Dorian B, Daret D, Demond-Henri J, Bricaud H. Role of cyclic AMP in the regulation of prostacyclin synthesis by cultured vascular smooth muscle cells. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984;17:585–592. 6328937.
45. Lippton HL, Chapnick BM, Hyman AL, Kadowitz PJ. Inhibition of vasoconstrictor responses by prostacyclin (PGI2) in the feline mesenteric vascular bed. Arch Int Pharmacodyn Ther 1979;241(2):214–223. 393194.
46. Llorens S, Miranda FJ, Alabadi JA, Marrachelli VG, Alborch E. Different role of endothelin ETA and ETB receptors and endothelial modulators in diabetes-induced hyperreactivity of the rabbit carotid artery to endothelin-1. Eur J Pharmacol 2004;486(1):43–51. 14751407.
47. Luksha L, Agewall S, Kublickiene K. Endotheliumderived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 2009;202(2):330–344. 18656197.
48. Maiorana A, O'Driscoll G, Cheetham C, Dembo L, Stanton K, Goodman C, Green D. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001;38(3):860–866. 11527646.
49. Meht JL, Lawson DL, Yang BC, Mehta P, Nichols WW. Modulation of vascular tone by endothelin-1: role of preload, endothelial integrity and concentration of endothelin-1. Br J Pharmacol 1992;106(1):127–132. 1324065.
50. Miche E, Herrmann G, Nowak M, Wirtz U, Tietz M, Hurst M, Radzewitz A. Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure. Clin Res Cardiol 2006;95 Suppl 1:i117–124. 16598538.
51. Middlebrooke AR, Elston LM, Macleod KM, Mawson DM, Ball CI, Shore AC, Tooke JE. Six months of aerobic exercise does not improve microvascular function in type 2 diabetes mellitus. Diabetologia 2006;49(10):2263–2271. 16944096.
52. Mombouli JV, Bissiriou I, Agboton V, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: a key mediator of the vasodilator action of bradykinin. Immunopharmacology 1996;33(1-3):46–50. 8856114.
53. Moncada S, Palmer RM, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989;38(11):1709–1715. 2567594.
54. Montero D, Walther G, Benamo E, Perez-Martin A, Vinet A. Effects of exercise training on arterial function in type 2 diabetes mellitus: a systematic review and meta-analysis. Sports Med 2013;43(11):1191–1199. 23912806.
55. Nagao T, Vanhoutte PM. Endothelium-derived hyperpolarizing factor and endothelium-dependent relaxations. Am J Respir Cell Mol Biol 1993;8(1):1–6. 8380248.
56. Ng KF, Leung SW, Man RY, Vanhoutte PM. Endothelium-derived hyperpolarizing factor mediated relaxations in pig coronary arteries do not involve Gi/o proteins. Acta Pharmacol Sin 2008;29(12):1419–1424. 19026160.
57. Okada S, Hiuge A, Makino H, Nagumo A, Takaki H, Konishi H, Miyamoto Y. Effect of exercise intervention on endothelial function and incidence of cardiovascular disease in patients with type 2 diabetes. J Atheroscler Thromb 2010;17(8):828–833. 20467191.
58. Ostergard T, Nyholm B, Hansen TK, Rasmussen LM, Ingerslev J, Sorensen KE, Schmitz O. Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training. Metabolism 2006;55(11):1508–1515. 17046554.
59. Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988;153(3):1251–1256. 3390182.
60. Pegoraro AA, Carretero OA, Sigmon DH, Beierwaltes WH. Sympathetic modulation of endothelium-derived relaxing factor. Hypertension 1992;19(6 Pt 2):643–647. 1350573.
61. Pieper GM, Riaz ulHaq. Activation of nuclear factorkappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol 1997;30(4):528–532. 9335415.
62. Pierce GL, Donato AJ, LaRocca TJ, Eskurza I, Silver AE, Seals DR. Habitually exercising older men do not demonstrate age-associated vascular endothelial oxidative stress. Aging Cell 2011;10(6):1032–1037. 21943306.
63. Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009;119(9):1284–1292. 19237660.
64. Pugliese G, Pricci F, Pugliese F, Mene P, Lenti L, Andreani D. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 1994;43(3):478–490. 8314022.
65. Rapoport RM, Draznin MB, Murad F. Endotheliumdependent vasodilator-and nitrovasodilator-induced relaxation may be mediated through cyclic GMP formation and cyclic GMP-dependent protein phosphorylation. Trans Assoc Am Physicians 1983;96:19–30. 6149646.
66. Rigla M, Fontcuberta J, Mateo J, Caixas A, Pou JM, de Leiva A, Perez A. Physical training decreases plasma thrombomodulin in type I and type II diabetic patients. Diabetologia 2001;44(6):693–699. 11440361.
67. Rognmo O, Hetland E, Helgerud J, Hoff J, Slordahl SA. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2004;11(3):216–222. 15179103.
68. Rush JW, Turk JR, Laughlin MH. Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium. Am J Physiol Heart Circ Physiol 2003;284(4):H1378–1387. 12595293.
69. Russell KS, Haynes MP, Caulin-Glaser T, Rosneck J, Sessa WC, Bender JR. Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J Biol Chem 2000;275(7):5026–5030. 10671543.
70. Sanchez R, MacKenzie A, Farhat N, Nguyen TD, Stewart DJ, Mercier I, Thorin E. Endothelin B receptormediated regulation of endothelin-1 content and release in cultured porcine aorta endothelial cell. J Cardiovasc Pharmacol 2002;39(5):652–659. 11973408.
71. Sayeski PP, Kudlow JE. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription. J Biol Chem 1996;271(25):15237–15243. 8663078.
72. Schoedon G, Blau N, Schneemann M, Flury G, Schaffner A. Nitric oxide production depends on preceding tetrahydrobiopterin synthesis by endothelial cells: selective suppression of induced nitric oxide production by sepiapterin reductase inhibitors. Biochem Biophys Res Commun 1994;199(2):504–510. 7510954.
73. Silver AE, Beske SD, Christou DD, Donato AJ, Moreau KL, Eskurza I, Seals DR. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 2007;115(5):627–637. 17242275.
74. Silver AE, Christou DD, Donato AJ, Beske SD, Moreau KL, Magerko KA, Seals DR. Protein expression in vascular endothelial cells obtained from human peripheral arteries and veins. J Vasc Res 2010;47(1):1–8. 19672102.
75. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74(3):247–253. 7547018.
76. Taylor SG, Weston AH. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988;9(8):272–274. 3074543.
77. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300(1):H2–12. 20952670.
78. Thom S, Hughes A, Martin G, Sever PS. Endotheliumdependent relaxation in isolated human arteries and veins. Clin Sci (Lond) 1987;73(5):547–552. 3119275.
79. Tjonna AE, Lee SJ, Rognmo O, Stolen TO, Bye A, Haram PM, Wisloff U. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation 2008;118(4):346–354. 18606913.
80. Touyz RM, Schiffrin EL. Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways. Hypertension 1997;30(2 Pt 1):222–229. 9260984.
81. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Goldberg IJ. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 2005;115(9):2434–2443. 16127462.
82. Williams B, Gallacher B, Patel H, Orme C. Glucoseinduced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46(9):1497–1503. 9287052.
83. Wisloff U, Ellingsen O, Kemi OJ. High-intensity interval training to maximize cardiac benefits of exercise training? Exerc Sport Sci Rev 2009;37(3):139–146. 19550205.
84. Wulfing P, Kersting C, Tio J, Fischer RJ, Wulfing C, Poremba C, Kiesel L. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 2004;10(7):2393–2400. 15073116.
85. Yamagishi SI, Edelstein D, Du XL, Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 2001;50(6):1491–1494. 11375352.
86. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010;59(1):249–255. 19833897.
87. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101(13):1539–1545. 10747347.
88. Zoppini G, Targher G, Zamboni C, Venturi C, Cacciatori V, Moghetti P, Muggeo M. Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2006;16(8):543–549. 17126770.
89. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004;11:89–97. 15370068.
90. A statistical table of the cause of death. 2010. Statistics Korea

Article information Continued

Fig. 1.

Endothelium-dependent vasoregulators.

Fig. 2.

Putative pathways associated with hyperglycemia-induced vascular endothelial dysfunction.